# Uracil mustard

Source: https://onco.cc/drugs/uracil-mustard/  
OnCo record `uracil-mustard` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Uracil mustard was an oral alkylating agent approved in 1962 for chronic lymphocytic leukaemia and lymphomas, one of the early nitrogen mustard tablets, and long since discontinued.

## Summary

Uracil mustard joined chlorambucil, melphalan and cyclophosphamide as the oral nitrogen mustards of the early 1960s and was approved in the United States in 1962 for chronic lymphocytic leukaemia, lymphomas including lymphosarcoma and reticulum cell sarcoma in the terminology of the day, and thrombocythaemia. Its results were similar to chlorambucil without clear advantages, and it was discontinued. It appears here for completeness of the alkylating agent story that began with the wartime nitrogen mustard studies.

## Fields

- Kind: Treatment
- Status: historic
- Last checked: 2026-09-08
- Tags: gap-fill; chembl-universe
- Brand: Uramustine
- Modality: Oral nitrogen mustard alkylating agent
- Mechanism: A nitrogen mustard attached to uracil that cross-links DNA strands; the uracil was intended to carry it into nucleic-acid-hungry cells.
- Approvals: US 1962: Chronic lymphocytic leukaemia, lymphomas and essential thrombocythaemia (historic label)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Uramustine
- Wikipedia: https://en.wikipedia.org/wiki/Uramustine
- ChEMBL CHEMBL1731: https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1731

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Chlorambucil](https://onco.cc/drugs/chlorambucil/)

---
JSON: https://onco.cc/api/v1/entities/uracil-mustard.json